KR20200118088A - 치료 화합물 및 조성물 - Google Patents
치료 화합물 및 조성물 Download PDFInfo
- Publication number
- KR20200118088A KR20200118088A KR1020207024907A KR20207024907A KR20200118088A KR 20200118088 A KR20200118088 A KR 20200118088A KR 1020207024907 A KR1020207024907 A KR 1020207024907A KR 20207024907 A KR20207024907 A KR 20207024907A KR 20200118088 A KR20200118088 A KR 20200118088A
- Authority
- KR
- South Korea
- Prior art keywords
- subject
- compound
- pharmaceutically acceptable
- acceptable salt
- effective amount
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Urology & Nephrology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Pulmonology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862627435P | 2018-02-07 | 2018-02-07 | |
| US62/627,435 | 2018-02-07 | ||
| PCT/US2019/016503 WO2019156929A1 (en) | 2018-02-07 | 2019-02-04 | Therapeutic compounds and compositions |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20200118088A true KR20200118088A (ko) | 2020-10-14 |
Family
ID=67548561
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020207024907A Pending KR20200118088A (ko) | 2018-02-07 | 2019-02-04 | 치료 화합물 및 조성물 |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US11691962B2 (https=) |
| EP (1) | EP3749662A4 (https=) |
| JP (2) | JP7397797B2 (https=) |
| KR (1) | KR20200118088A (https=) |
| CN (1) | CN111902404A (https=) |
| AU (1) | AU2019217366B2 (https=) |
| BR (1) | BR112020016123A2 (https=) |
| CA (1) | CA3089970A1 (https=) |
| IL (2) | IL276563B1 (https=) |
| WO (1) | WO2019156929A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2733405C2 (ru) | 2014-02-07 | 2020-10-01 | Экзитера Фармасьютикалз Инк. | Терапевтические соединения и композиции |
| CA3089970A1 (en) | 2018-02-07 | 2019-08-15 | eXIthera Pharmaceuticals Inc. | Therapeutic compounds and compositions |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4595532A (en) | 1983-02-02 | 1986-06-17 | University Of Notre Dame Du Lac | N-(substituted-methyl)-azetidin-2-ones |
| JP2002501081A (ja) | 1998-01-26 | 2002-01-15 | ビーエーエスエフ アクチェンゲゼルシャフト | トロンビンインヒビター |
| HUP0104308A3 (en) | 1998-06-25 | 2002-06-28 | Bristol Myers Squibb Co | Amidino and guanidino azetidinone derivatives as tryptase inhibitors, process for their preparation, pharmaceutical compositions thereof and intermediates |
| US6335324B1 (en) | 1998-06-25 | 2002-01-01 | Bristol-Myers Squibb Co. | Beta lactam compounds and their use as inhibitors of tryptase |
| EP1099690A4 (en) | 1998-07-23 | 2001-10-17 | Shionogi & Co | MONOCYCLIC BETA LACTAM COMPOUNDS AND CHYMASE INHIBITORS THAT CONTAIN THEM |
| KR20060120601A (ko) | 2003-08-22 | 2006-11-27 | 데이진 화-마 가부시키가이샤 | 키마제 저해제를 유효 성분으로서 함유하는 약제 |
| EP1871741A4 (en) | 2005-04-04 | 2012-01-11 | Daiamed Inc | SUBSTITUTED AZETIDINONE |
| TW200745084A (en) | 2006-03-08 | 2007-12-16 | Astrazeneca Ab | Novel compounds |
| JP5756800B2 (ja) | 2009-06-16 | 2015-07-29 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Ｃｂ２受容体を調節するアゼチジン２−カルボキサミド誘導体 |
| NZ602266A (en) | 2010-02-11 | 2014-05-30 | Bristol Myers Squibb Co | Macrocycles as factor xia inhibitors |
| JP6033319B2 (ja) | 2011-10-14 | 2016-11-30 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | 第ＸＩａ因子阻害剤としての置換テトラヒドロイソキノリン化合物 |
| SG11201406142XA (en) | 2012-03-27 | 2014-10-30 | Univ Duke | Compositions and methods for the prevention and treatment of mast cell-induced vascular leakage |
| RU2733405C2 (ru) * | 2014-02-07 | 2020-10-01 | Экзитера Фармасьютикалз Инк. | Терапевтические соединения и композиции |
| US20190315711A1 (en) | 2016-12-23 | 2019-10-17 | Exithera Pharmaceuticals, Inc. | Therapeutic compounds and compositions |
| CA3089970A1 (en) | 2018-02-07 | 2019-08-15 | eXIthera Pharmaceuticals Inc. | Therapeutic compounds and compositions |
| JP2022506110A (ja) | 2018-10-30 | 2022-01-17 | エクセセーラ ファーマシューティカルズ インコーポレイテッド | 治療用化合物および組成物 |
| CN113056263A (zh) | 2018-10-30 | 2021-06-29 | 艾克赛特赫拉制药有限责任公司 | 治疗化合物和组合物 |
| JP2022523712A (ja) | 2019-01-29 | 2022-04-26 | エクセセーラ ファーマシューティカルズ インコーポレイテッド | 治療用化合物および組成物 |
-
2019
- 2019-02-04 CA CA3089970A patent/CA3089970A1/en active Pending
- 2019-02-04 KR KR1020207024907A patent/KR20200118088A/ko active Pending
- 2019-02-04 CN CN201980021810.6A patent/CN111902404A/zh active Pending
- 2019-02-04 EP EP19751349.2A patent/EP3749662A4/en not_active Withdrawn
- 2019-02-04 WO PCT/US2019/016503 patent/WO2019156929A1/en not_active Ceased
- 2019-02-04 BR BR112020016123-3A patent/BR112020016123A2/pt unknown
- 2019-02-04 AU AU2019217366A patent/AU2019217366B2/en active Active
- 2019-02-04 JP JP2020542552A patent/JP7397797B2/ja active Active
-
2020
- 2020-08-06 US US16/986,658 patent/US11691962B2/en active Active
- 2020-08-06 IL IL276563A patent/IL276563B1/en unknown
-
2023
- 2023-02-17 US US18/170,858 patent/US12152014B2/en active Active
- 2023-12-01 JP JP2023203652A patent/JP2024023490A/ja active Pending
-
2025
- 2025-12-21 IL IL325484A patent/IL325484A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2019217366A1 (en) | 2020-08-20 |
| US20240059670A1 (en) | 2024-02-22 |
| CA3089970A1 (en) | 2019-08-15 |
| US12152014B2 (en) | 2024-11-26 |
| WO2019156929A1 (en) | 2019-08-15 |
| JP2021512894A (ja) | 2021-05-20 |
| RU2020129237A (ru) | 2022-03-09 |
| IL276563A (en) | 2020-09-30 |
| JP7397797B2 (ja) | 2023-12-13 |
| AU2019217366B2 (en) | 2024-07-11 |
| EP3749662A4 (en) | 2021-07-14 |
| IL325484A (en) | 2026-02-01 |
| US20210188812A1 (en) | 2021-06-24 |
| BR112020016123A2 (pt) | 2021-02-23 |
| JP2024023490A (ja) | 2024-02-21 |
| CN111902404A (zh) | 2020-11-06 |
| IL276563B1 (en) | 2026-01-01 |
| EP3749662A1 (en) | 2020-12-16 |
| US11691962B2 (en) | 2023-07-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12084414B2 (en) | Therapeutic compounds and compositions | |
| US20210261524A1 (en) | Therapeutic compounds and compositions | |
| WO2018118705A1 (en) | Therapeutic compounds and compositions | |
| JP2024023490A (ja) | 治療用化合物および組成物 | |
| US20210253550A1 (en) | Therapeutic compounds and compositions | |
| JP2023518262A (ja) | Ｐｈｄ阻害剤化合物、組成物、及び使用 | |
| RU2817800C2 (ru) | Терапевтические соединения и композиции | |
| HK1230083B (zh) | 治療化合物和組合物 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
Patent event date: 20200828 Patent event code: PA01051R01D Comment text: International Patent Application |
|
| PG1501 | Laying open of application | ||
| A201 | Request for examination | ||
| PA0201 | Request for examination |
Patent event code: PA02012R01D Patent event date: 20220204 Comment text: Request for Examination of Application |
|
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
Comment text: Notification of reason for refusal Patent event date: 20240401 Patent event code: PE09021S01D |
|
| E701 | Decision to grant or registration of patent right | ||
| PE0701 | Decision of registration |
Patent event code: PE07011S01D Comment text: Decision to Grant Registration Patent event date: 20250122 |